GT Biopharma
GT Biopharma, a global biotech firm, develops innovative drugs for cancer, myeloma, and other medical needs.
Founded
1973GT Biopharma, a global biotech firm, develops innovative drugs for cancer, myeloma, and other medical needs.
GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical-stage immuno-oncology company founded with the mission to develop innovative therapies for cancer and other unmet medical needs. Utilizing their proprietary NK cell engager (TriKE®) technology, GT Biopharma focuses on generating novel biopharmaceutical drugs targeting various cancers, including acute lymphocytic leukemia, non-Hodgkin's lymphoma, acute myeloid leukemia, and multiple solid tumors. The company's core vision is to revolutionize cancer treatment through advanced immunotherapy solutions.
Notable figures associated with GT Biopharma include key scientists and executives with extensive backgrounds in biotechnology and oncology. The company has attracted significant investment from both private and institutional investors, reflecting strong confidence in its potential. Key achievements include progressing several drug candidates into clinical trials and demonstrating promising preliminary results. GT Biopharma's impact lies in its potential to offer new hope to cancer patients worldwide through cutting-edge immunotherapy treatments.
Companies similar to GT Biopharma include NextCure, Indapta Therapeutics, Forte Biosciences and Gritstone bio.
GT Biopharma was founded in 1973.
GT Biopharma's headquarters is located in Brisbane, CA, US.
GT Biopharma's most recent funding round was for $6.5M (USD) in December 2022.
As of Dec 30, 2022, GT Biopharma has disclosed funding of $71.1M (USD). Undisclosed round amounts are excluded.
GT Biopharma has 8 employees as of Feb 6, 2024.
Gritstone bio
gritstonebio.com
